NCT07740720Not yet recruitingPhase 3
A Phase 3b, Open-label Study Investigating the Duration of Neoadjuvant Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- GlaxoSmithKline
- Enrollment
- 90
- Primary Endpoint
- Percentage of participants who achieve clinical complete response (cCR) amongst participants who receive > 9 cycles (> 6 months) of dostarlimab monotherapy by investigator assessment
Study Overview
Brief Summary
This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to treatment and avoid standard treatments like chemotherapy, radiation treatment, or surgery. Scans and endoscopy tests will be conducted to see if the tumor disappears and how long the cancer stays under control. The study will also collect information on side effects and health outcomes after dostarlimab.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Has histologically confirmed Stage II to III (T3-T4, N0, or T any, N+) locally advanced rectal adenocarcinoma.
- •Has radiologically and endoscopically evaluable disease.
- •Has a tumor demonstrating the presence of either:
- •dMMR status; MMR status must be assessed by immunohistochemistry for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of 1 or more proteins indicates dMMR; MMR status will be determined locally; or
- •MSI-H phenotype as determined by polymerase chain reaction or by tissue next generation sequencing; MSI-H will be determined locally.
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Has adequate organ function.
Exclusion Criteria
- •Has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer.
- •Has a tumor that, in the investigator's judgment, is causing symptomatic bowel obstruction or otherwise requires urgent/emergent local intervention. Participants with a history of bowel obstruction are eligible after obstruction is relieved by a diverting stoma (defunctioning colostomy). Patients with a history of bowel obstruction in the context of current rectal cancer diagnosis and treated with stenting are not eligible.
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
- •Has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to enrollment.
- •Is receiving any other anticancer or experimental therapy.
Outcomes
Primary Outcomes
Percentage of participants who achieve clinical complete response (cCR) amongst participants who receive > 9 cycles (> 6 months) of dostarlimab monotherapy by investigator assessment
Time Frame: Up to 168 weeks
Secondary Outcomes
- Overall cCR rate by investigator assessment(Up to 171 weeks)
- Number of participants with sustained clinical complete response at 12 months (cCR12) as assessed by investigator(Up to 171 weeks)
- Objective response rate (ORR) as assessed by investigator(Up to 171 weeks)
- Number of participants with composite cCR12 and pathologic complete response (pCR) as assessed by investigator(Up to 171 weeks)
- Time to cCR(Up to 171 weeks)
- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse event (imAEs), and AEs leading to death or discontinuation of study intervention by severity(Up to 171 weeks)
Investigators
Similar Trials
Not yet recruiting
Phase 2
A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal CancerNCT07402486Siriraj Hospital20
Recruiting
Not Applicable
Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal NeoplasiaNCT07632196Althaia Xarxa Assistencial Universitària de Manresa84
Active, not recruiting
Phase 3
A study to evaluate the efficacy, safety and immunogenicity of Bevacizumab in metastatic colorectal cancer patients.CTRI/2024/04/066032CuraTeQ Biologics Private Ltd168
Not yet recruiting
Not Applicable
Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant TreatmentRectal CancerNCT07404228Institut du Cancer de Montpellier - Val d'Aurelle115
Not yet recruiting
Phase 2
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal CancerNCT07397442Beijing Friendship Hospital19